Skip to main content

Table 2 BCMA-targeted CAR-T cell products in clinical trials

From: BCMA-targeted immunotherapy for multiple myeloma

Name Manufacturer BCMA scFv Co-stimulatory Transduction Extra safety domain
CAR-BCMA NCI Murine CD28 γ-Retrovirus No
Idecabtagene vicleucel; Bb2121 Bluebird Bio and Celgene Murine 4-1BB Lentivirus No
Bb21217 Bluebird Bio and Celgene Murine 4-1BB Lentivirus Yes, PI3K inhibitor
LCAR-B38M Nanjing Legend/Genscript Biotech Bi-epitope 4-1BB Lentivirus No
JNJ-4528 Janssen Research & Development Bi-epitope 4-1BB Lentivirus No
CT053 CARsgen Therapeutics Fully human 4-1BB Lentivirus No
P-BCMA-101 Poseida Therapeutics Fully human anti-BCMA CentyrinTM 4-1BB PiggyBac™ (PB) DNA Modification System No
CART-BCMA UPenn/Novartis Fully human 4-1BB Lentivirus No
CT103A Nanjing laso Biotherapeutics Fully human 4-1BB Lentivirus No
JCARH125 Juno Therapeutics Fully human 4-1BB Lentivirus No
MCARH171 MSKCC Fully human 4-1BB γ-Retrovirus Yes, tEGFR
BCMA CAR-T HRAIN Biotech Fully human 4-1BB γ-Retrovirus Yes, tEGFR
KITE-585 Kite, Gilead company Fully human CD28 Lentivirus No